Contineum Therapeutics, Inc.
CTNM
$11.01
$0.575.46%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 27.81% | 31.78% | 104.37% | 128.72% | 95.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.09% | 63.58% | 82.38% | 76.18% | 60.79% |
| Operating Income | -15.09% | -63.58% | -82.38% | -76.18% | -60.79% |
| Income Before Tax | -24.59% | -78.04% | -89.97% | -83.67% | -61.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.59% | -78.04% | -89.97% | -87.48% | -64.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.59% | -78.04% | -89.97% | -87.48% | -64.25% |
| EBIT | -15.09% | -63.58% | -82.38% | -76.18% | -60.79% |
| EBITDA | -15.02% | -63.75% | -82.71% | -76.08% | -60.88% |
| EPS Basic | -14.04% | -60.59% | 82.60% | -10.63% | 85.16% |
| Normalized Basic EPS | -14.03% | -60.56% | 82.60% | 83.34% | 85.44% |
| EPS Diluted | -14.04% | -60.59% | 82.60% | -10.63% | 85.17% |
| Normalized Diluted EPS | -14.03% | -60.56% | 82.60% | 83.34% | 85.44% |
| Average Basic Shares Outstanding | 9.27% | 10.88% | 991.93% | 1,002.58% | 1,006.86% |
| Average Diluted Shares Outstanding | 9.27% | 10.88% | 991.93% | 1,002.58% | 1,006.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |